Myesha Lacy
Investor Relations Kontakt bei ARCELLX, INC.
Profil
Myesha Lacy is currently the Vice President-Investor Relations at Arcellx, Inc. She previously worked as the Director-Investor Relations & Communications at Hyperion Therapeutics, Senior Director-Investor Relations at ZS Pharma, Vice President-Investor Relations & Communications at Global Blood Therapeutics, and Vice President-Investor Relations & Communications at Adverum Biotechnologies.
She completed her undergraduate degree at Holy Names University.
Aktive Positionen von Myesha Lacy
| Unternehmen | Position | Beginn |
|---|---|---|
| ARCELLX, INC. | Investor Relations Kontakt | 01.06.2021 |
Ehemalige bekannte Positionen von Myesha Lacy
| Unternehmen | Position | Ende |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Investor Relations Kontakt | - |
| ZS PHARMA INC | Investor Relations Kontakt | - |
| HYPERION THERAPEUTICS INC | Investor Relations Kontakt | - |
| GLOBAL BLOOD THERAPEUTICS, INC. | Investor Relations Kontakt | - |
Ausbildung von Myesha Lacy
| Holy Names University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ARCELLX, INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
